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stress is one of the most important psychological background factors of before time 
mortality in Hungary.
PMH20
IMPACT OF DISEASE SEVERITY ON DURATION OF HOSPITALIZATION 
IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH OLANZAPINE 
OR HALOPERIDOL IN GERMANY: POST-HOC ANALYSIS OF DATA 
COLLECTED IN THE GEO STUDY
Clouth J1, Schmidt P2, Möser G3, Eichmann F4, Breitscheidel L4
1Lilly Deutschland GmbH, Bad Homburg, Germany, 2University of Giessen, Giessen, 
Germany, 3Masem Research Institute, Giessen, Germany, 4Kendle GmbH, Munich, Germany
OBJECTIVES: To determine the impact of disease severity on duration of hospitali-          
zation in patients with schizophrenia in presence of the confounding variables.
METHODS: A post-hoc analysis of data collected in the GEO study, a prospective,            
non-interventional study observing German patients (n  655) with schizophrenia 
(ICD-10, F20) for up to two years was undertaken. Patients provided informed 
consent and were documented in inpatient (psychiatric clinics) and outpatient (psy-
chiatric ofﬁces, hospital outpatient wards) settings. Disease severity was measured by 
the Clinical Global Impression scale (CGI), which consists of Severity of Illness, Global 
Improvement, and Efﬁcacy Index items. Structural equation modelling (SEM) was 
applied to evaluate the impact of disease severity on duration of hospitalization. 
Confounding variables (age at diagnosis, gender and treatment regimen) were tested 
in the models evaluating the inﬂuence of disease severity on duration of hospitaliza-
tion. The models were tested in an exploratory way using the Mplus Version 5.2. All 
indices (C2, P, C2/df, CFI, RMSEA, PCLOSE) suggested a good model ﬁt. RESULTS: 
Patients (52.7% males) were on average 41.7 years old, had a mean BMI of 26.4 kg/ 
m2, were statutorily insured (97.0%), predominantly single (60.8%) and not employed 
(71.2%) at enrolment. Age at diagnosis, antipsychotic treatment regimen and disease 
severity were independently associated with duration of hospitalization (B  0.127, 
0.270 and 0.174, respectively), indicating that younger age at diagnosis of schizophre-
nia, treatment with olanzapine and less severe disease condition are associated with 
shorter duration of hospitalization. Gender had no effect on duration of hospitaliza-
tion (B  0.027). CONCLUSIONS: Treatment regimen and age at diagnosis play an        
important role in the associations between disease severity and duration of hospitaliza-
tion. Advanced techniques such as SEM are important tools for analyzing data in that 
they are able to detect associations, which univariate tests may fail to identify. Further 
research is needed to conﬁrm our ﬁndings.
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OBJECTIVES: To estimate the impact of duloxetine reimbursement in major depres-
sive disorder (MDD) treatment on public payer’s budget in Poland. METHODS: The 
analysis was performed in 5-year time horizon from the public payer (National Health 
Fund, NFZ) perspective . Only costs of medicines were included. On the base of sales 
data for years 2004–2008 linear regression was conducted to predict consumption of 
antidepressants in Poland. Cost data of medicines were obtained from Ministry of 
Health and other sources in case of lack of reimbursement. Duloxetine market share 
and alternative medicines replacement was estimated on the base of antidepressants 
sale data from European countries. One-way sensitivity analysis were performed for 
the key input parameters. RESULTS: Assuming that duloxetine is not reimbursed the 
expenditure on all antidepressants from NHF perspective will be 138.83 milion PLN 
(mPLN) in year 2010 and 171.37 mPLN in year 2014. In case of reimbursement of 
duloxetine the expenditures will increase by 0.07 mPLN in year 2010 and by 8.82 
mPLN in year 2014. CONCLUSIONS: Our ﬁndings suggest that decision concerning 
reimbursement of duloxetine should not lead to important increase of total expendi-
tures on the MDD treatment from on public payer’s perspective.
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OBJECTIVES: Social health insurance cost of care for patients with schizophrenia 
(ICD-10: F20-F25) are mainly inﬂuenced by hospitalization and use of antipsychotic 
medication. We determined the budget impact of long acting injectable risperidone 
(RLAI) for the German health care system in comparison to other antipsychotics 
(N05A, N05A1, Quetiapine). METHODS: The perspective of the social health insur-
ance (GKV) was adopted (one year time horizon). An Excel(R) based hypothetical 
budget impact model calculating cost consequences of using antipsychotic medication 
was developed accounting for hospital and medication cost only. Patient numbers and 
prescription shares were calculated using IMS-Health Disease Analyzer data. Medica-
tion costs are GKV net costs calculated by using recent list prices (06/09) and GKV 
utilization data. Parameters on hospitalization and relapse were derived from pub-
lished literature, Federal Ofﬁce of statistics and clinical trial data. Starting from status 
quo we speciﬁcally looked at new patients to be treated with antipsychotics. In a base 
case we assumed that new patients were distributed to the existing treatment options 
according to current patient share. Starting from this we hypothetically increased the 
patient share of RLAI by lowering the share of other antipsychotic treatments. 
RESULTS: We included 192,732 patients. 8000 new patients were added, 304 of 
which were treated with RLAI, 673 with Quetiapine. Costs for new patients would 
be a48,641,318. Increasing the treatment share of RLAI to 5% by shifting patients 
from Quetiapine to RLAI would decrease costs to a48,543,486 with increased medica-
tion cost being more than offset by decreased hospitalization costs. Switching new 
patients from all N05A1 treatments would decrease costs to a48,625,655. Sensitivity 
analysis conﬁrmed the result that increasing treatment with RLAI would save costs. 
CONCLUSIONS: Our analysis suggests that extending the patient share of RLAI in 
new patients suffering from schizophrenia would decrease the overall cost spent on 
medication and hospitalization.
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OBJECTIVES: This study was intended to provide a detailed account of the labelled 
drug-related health expenditure of countries in Europe in 2005, and make a compre-
hensive assessment of the spending by considering the health spending to GDP ratio 
and the health spending per capita. METHODS: In 2007, the European Monitoring 
Centre for Drugs and Drug Addiction network of national focal points (NFPs) set up 
in the 27 EU Member States, Norway, and the candidate countries to the EU, identiﬁed 
labelled drug-related expenditure per country. The NFPs were asked to list any budg-
eted drug-related funds found after reviewing central, regional and local government 
ﬁnancial reports for the 2005 ﬁscal year. Labelled expenditure was classiﬁed by means 
of the International Classiﬁcation of the Functions of Government (COFOG). 
RESULTS: Health expenditure was reported by 10 countries. Total amount reported 
was a1.38 billion, the highest proportion being under outpatient (68%) and hospital 
services (16%), followed by medical products (7%) and public health services (7%). 
By country, labelled health expenditures ranged from a0.1 million (Slovakia) to a923.3 
million (UK), representing between 0.0003% and 0.051% of their GDP respectively. 
When plotted, the health expenditure per capita showed a positive association with 
the GDP per capita across countries (r  0.70). While there is an overall tendency for 
countries with higher GDP to spend a greater proportion of their GDP on drug-related 
health, there is a wide variation since GDP is not the sole factor inﬂuencing health 
expenditure amounts. CONCLUSIONS: Several countries have a considerable amount 
and quality of information on drug-related health public expenditure, facilitating 
public analysis and debate. These ﬁgures are ultimately intended to enhance policy-
makers’ decision-making on drug-related health policy. Public expenditure must even-
tually be complemented by undertaking economic evaluations where expenditure is 
considered in the perspective of the beneﬁts obtained by its allocation.
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OBJECTIVES: To compare costs of treating patients with major depressive disorder 
(MDD) with escitalopram versus duloxetine in Spain and to assess the 5-year budget-
ary impact (BI) of different scenarios of escitalopram and duloxetine market share 
dynamics. METHODS: An evaluation of 6-month per patient costs associated with 
escitalopram versus duloxetine treatment was conducted alongside a 24-week double-
blind randomized multinational study in adult outpatients with MDD. Health care 
resource use and sick leave were evaluated using a Health Economic Assessment 
questionnaire. Unit costs of health care services were obtained from standard Spanish 
sources. For the 5-year BI analyses, scenario 1 based the growth of escitalopram and 
duloxetine market shares on conservative Spanish forecasts; scenario 2 assumed a 
higher growth of escitalopram share in MDD due to its superior clinical proﬁle, with 
a conservative 1% annual intake from duloxetine market share growth rate. Popula-
tion and MDD prevalence data were obtained from standard Spanish sources. 
RESULTS: For the total 24-week study period, per patient costs were a986 for esci-
talopram and a1,593 for duloxetine – a savings of a608 in favor of escitalopram. Sick 
leave was the major driver of overall cost in both treatment groups (60–70%). Given 
a Spanish population of 45.2 million and 4% prevalence of MDD, the BI analysis 
revealed treatment with escitalopram yielded savings amounting to a174 million over 
5 years for the total patient cohort. CONCLUSIONS: Escitalopram is associated 
with signiﬁcant cost savings compared with duloxetine. Indirect costs of sick leave 
accounted for the greatest portion of total costs. Reduced health care use and sick 
leave costs suggest that escitalopram could be a preferred therapeutic alternative to 
duloxetine in treating MDD, thereby bringing substantial overall cost savings over 5 
years and providing additional evidence that escitalopram is an attractive option for 
ﬁrst-line treatment of MDD in Spain.
